安能得胰臟癌:安能得<sup>®<sup>
安能得<sup>®<sup>
Provide From Google
![智擎ONIVYDE® (安能得®) 取得中國新藥上市銷售許可](https://i0.wp.com/api.multiavatar.com/%E6%99%BA%E6%93%8EONIVYDE%C2%AE+%28%E5%AE%89%E8%83%BD%E5%BE%97%C2%AE%29+%E5%8F%96%E5%BE%97%E4%B8%AD%E5%9C%8B%E6%96%B0%E8%97%A5%E4%B8%8A%E5%B8%82%E9%8A%B7%E5%94%AE%E8%A8%B1%E5%8F%AF.png?apikey=viVnb6N20jclO8)
智擎ONIVYDE® (安能得®) 取得中國新藥上市銷售許可
https://www.pharmaengine.com
Provide From Google
![全球第一個證實可延長轉移性胰腺癌患者整體存活期台灣 ...](https://i0.wp.com/api.multiavatar.com/%E5%85%A8%E7%90%83%E7%AC%AC%E4%B8%80%E5%80%8B%E8%AD%89%E5%AF%A6%E5%8F%AF%E5%BB%B6%E9%95%B7%E8%BD%89%E7%A7%BB%E6%80%A7%E8%83%B0%E8%85%BA%E7%99%8C%E6%82%A3%E8%80%85%E6%95%B4%E9%AB%94%E5%AD%98%E6%B4%BB%E6%9C%9F%E5%8F%B0%E7%81%A3+....png?apikey=viVnb6N20jclO8)
全球第一個證實可延長轉移性胰腺癌患者整體存活期台灣 ...
https://www.mohw.gov.tw
過去全世界胰臟癌第一線標準治療藥物主要是以gemcitabine為基礎之療法,在ONIVYDETM(安能得R)成功上市前,對於使用gemcitabine治療後失敗的胰腺癌病人,尚無法規核准 ...
Provide From Google
![一線胰臟癌上半年送藥證申請,智擎安能得動能可期](https://i0.wp.com/api.multiavatar.com/%E4%B8%80%E7%B7%9A%E8%83%B0%E8%87%9F%E7%99%8C%E4%B8%8A%E5%8D%8A%E5%B9%B4%E9%80%81%E8%97%A5%E8%AD%89%E7%94%B3%E8%AB%8B%EF%BC%8C%E6%99%BA%E6%93%8E%E5%AE%89%E8%83%BD%E5%BE%97%E5%8B%95%E8%83%BD%E5%8F%AF%E6%9C%9F.png?apikey=viVnb6N20jclO8)
一線胰臟癌上半年送藥證申請,智擎安能得動能可期
https://www.moneydj.com
IPSEN也計畫上半年將送出擴大安能得適應症延伸的美國藥證申請,並搭配去年取得的快速審批資格,一般預料,6-9個月藥證可望到手,未來也有機會擴及歐亞市場 ...
Provide From Google
![智擎安能得用於一線胰臟癌解盲成功,市場規模將增2](https://i0.wp.com/api.multiavatar.com/%E6%99%BA%E6%93%8E%E5%AE%89%E8%83%BD%E5%BE%97%E7%94%A8%E6%96%BC%E4%B8%80%E7%B7%9A%E8%83%B0%E8%87%9F%E7%99%8C%E8%A7%A3%E7%9B%B2%E6%88%90%E5%8A%9F%EF%BC%8C%E5%B8%82%E5%A0%B4%E8%A6%8F%E6%A8%A1%E5%B0%87%E5%A2%9E2-5%E5%80%8D.png?apikey=viVnb6N20jclO8)
智擎安能得用於一線胰臟癌解盲成功,市場規模將增2
https://tw.tech.yahoo.com
智擎9日下午公告,已上市銷售、原本屬於胰腺癌二、三線用藥的安能得,挺進線治療的組合療法NALIRIFOX之全球樞紐性臨床試驗,9日公布結果達顯著臨床意義, ...
Provide From Google
![智擎胰臟癌新藥向歐洲申請新適應症最快明年上半年通過核准](https://i0.wp.com/api.multiavatar.com/%E6%99%BA%E6%93%8E%E8%83%B0%E8%87%9F%E7%99%8C%E6%96%B0%E8%97%A5%E5%90%91%E6%AD%90%E6%B4%B2%E7%94%B3%E8%AB%8B%E6%96%B0%E9%81%A9%E6%87%89%E7%97%87%E6%9C%80%E5%BF%AB%E6%98%8E%E5%B9%B4%E4%B8%8A%E5%8D%8A%E5%B9%B4%E9%80%9A%E9%81%8E%E6%A0%B8%E5%87%86.png?apikey=viVnb6N20jclO8)
智擎胰臟癌新藥向歐洲申請新適應症最快明年上半年通過核准
https://tw.stock.yahoo.com
智擎表示,安能得新適應症為適用於轉移性胰腺癌,合併oxaliplatin、5-fluorouracil 和leucovorin 用藥並作為病人的第一線治療,而歐洲藥品管理局正式接受 ...
Provide From Google
![《生技投資》胰臟癌新藥安能得(ONIVYDE) 一線用藥全球三期 ...](https://i0.wp.com/api.multiavatar.com/%E3%80%8A%E7%94%9F%E6%8A%80%E6%8A%95%E8%B3%87%E3%80%8B%E8%83%B0%E8%87%9F%E7%99%8C%E6%96%B0%E8%97%A5%E5%AE%89%E8%83%BD%E5%BE%97%28ONIVYDE%29+%E4%B8%80%E7%B7%9A%E7%94%A8%E8%97%A5%E5%85%A8%E7%90%83%E4%B8%89%E6%9C%9F+....png?apikey=viVnb6N20jclO8)
《生技投資》胰臟癌新藥安能得(ONIVYDE) 一線用藥全球三期 ...
http://www.genetinfo.com
法國Ipsen公司安能得組合療法NALIRIFOX於一線胰腺癌之全球樞紐性臨床試驗結果達顯著臨床意義,帶動Ipsen股價大漲4.15%收105.4歐元,以及授權給Ipsen ...